Tenecteplase: Stability and bioactivity of thawed or diluted solutions used in peripheral thrombolysis

Journal of Vascular and Interventional Radiology

Volumn 14, Issue 4, 2003, Pages 475-479

  Semba, Charles P ^a,b   Weck, Suzanne ^a   Razavi, Mahmood K ^b   Tuomi, Lisa ^a,b   Patapoff, Thomas ^a  

^a GENENTECH INC   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CATHFLO ACTIVASE; MONOMER; PLASMINOGEN ACTIVATOR; PROTEIN; SODIUM CHLORIDE; TENECTEPLASE; TNK; WATER;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL PRACTICE; CONCENTRATION (PARAMETERS); DILUTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; ENVIRONMENTAL TEMPERATURE; FREEZING; HEART INFARCTION; IN VITRO STUDY; OPTICS; PH; PRECIPITATION; PRIORITY JOURNAL; PROTEIN CONTENT; THAWING;

EID: 0037387980     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000064843.87207.F7     Document Type: Article

References (14)

1. TNKase full prescribing information. In: 2002 Physicians' Desk Reference. Montvale, NJ: Thomas Medical Economics, 2002.
2. Refino CJ, Paoni NF, Keyt BA, et al. A variant of t-PA T103N, KHRR296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993; 70:313-319.
3. Keyt B, Paoni NF, Refino CJ, et al. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994; 91:3670-3674.
4. Collen D, Stassen JM, Yasuda T, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72:98-104.
5. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human recombinant tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared to recombinant TPA. Circulation 1995; 92:3032-3040.
6. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators (ASSENT-2). Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double blind randomized trial Lancet 1999; 354:716-722.
7. Semba CP, Sugimoto K, Razavi MK. Alteplase and tenecteplase: applications in the peripheral circulation. Tech Vasc Intervent Radiol 2001; 4:99-106.
8. Sze DY, Carey MB, Razavi MK. Treatment of massive pulmonary embolism with catheter-directed tenecteplase. J Vasc Interv Radiol 2001; 12: 1456-1457.
9. Razavi MK, Wong H, Sze DY, Kee ST, Semba CP, Dake MD. Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy. J Endovasc Ther 2002; 9:593-598.
10. Burkhart DJ, Borsa JJ, Anthony JP, Thurlo SR. Thrombolysis of occluded peripheral arteries and veins with tenecteplase: pilot study. J Vasc Interv Radiol 2002; 13:1099-1102.
11. Nehme TN, Beres RA, Sane S, Minor P, Olson D. Tenecteplase for the lyse and wait technique in recanalization of thrombosed PTFE hemodialysis grafts [abstract]. J Vasc Interv Radiol 2002; 13(suppl):S109.
12. Calis KA, Cullinane AM, Horne MK. Bioactivity of cryopreserved alteplase solutions. Am J Health Syst Pharm 1999; 56:2056-2057.
13. Jones AJ, Meunier AM. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Thromb Haemost 1990; 64:455-463.
14. Cornelius RM, Archambault JG, Berry L, Chan AK, Brash JL. Adsorption of protein from infant and adult plasma to biomaterial surfaces. J Biomed Mater Res 2000; 15:622-632.